Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

Open Forum Infect Dis. 2021 Jan 20;8(1):ofaa629. doi: 10.1093/ofid/ofaa629. eCollection 2021 Jan.

Authors

Yoav Golan¹, Herbert L DuPont^{2

3}, Fernando Aldomiro⁴, Erin H Jensen⁵, Mary E Hanson⁵, Mary Beth Dorr⁵

Affiliations

¹ Tufts Medical Center, Boston, Massachusetts, USA.
² University of Texas School of Public Health, Houston, Texas, USA.
³ Baylor St. Luke's Medical Center, Houston, Texas, USA.
⁴ Hospital Fernando Fonseca, EPE - Amadora/Sintra at Portugal, Area Metropolitana de Lisboa, Carnaxide, Portugal.
⁵ Merck & Co., Inc., Kenilworth, New Jersey, USA.

Abstract

[This corrects the article DOI: 10.1093/ofid/ofaa248.].

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Publication types

Published Erratum